Alert detail

LCD L39469: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis — Noridian

Policy ID: LCD-L39469Specialty: RheumatologyAdded: 6/5/2026Effective: August 7, 2025lcd
High

What changed

New billing guidelines for rheumatoid arthritis testing set for 2025.

Who’s affected: Rheumatology billing teams · Effective: August 7, 2025

Affected codes

Codes81599

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

This change affects 6 billing codes.

The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.